Investigation of the cell based therapy for primary lung dysfunction after lung transplantation using mesenchymal stem cell

• Project/Area Number: 26870042
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: General surgery; Respiratory surgery
• Research Institution: Tohoku University
• Principal Investigator: Tatsuaki Watanabe 東北大学, 加齢医学研究所, 非常勤講師 (70636034)
• Project Period (FY): 2014-04-01 – 2016-03-31
• Project Status: Completed (Fiscal Year 2015)
• Budget Amount: ¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000); Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000); Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
• Keywords: 肺移植 / 細胞治療 / 虚血再灌流障害 / 間葉系幹細胞 / 胸部外科 / 移植 / 臓器保存

Outline of Final Research Achievements

Primary graft dysfunction is a major cause of morbidity and mortality after lung transplantation. Mesenchymal stem cells (MSCs) have a suppress inflammation and immune responses. We examined whether MSCs attenuate ischemia-reperfusion injury in a mouse model of lung transplantation. Mouse lungs were preserved at 4°C for 18 h. Human MSCs were injected into the lung grafts, and orthotopic left lung transplantation was performed. The lung isografts were reperfused for 6 hours. Protein concentration and cell count in Bronchioalveolar lavage fluid were significantly lower in the MSC-administered grafts than in the PBS-administered controls. Concentrations of proinflammatory cytokines showed a decreasing trend in the MSC-administered grafts compared with the controls.Pretransplant administration of MSC may attenuate ischemia-reperfusion injury after prolonged cold ischemia in the mouse model of lung transplantation.

Research Products

• [Remarks] 細胞治療による虚血再灌流性肺傷害制御に関わる研究
  • URL: http://www2.idac.tohoku.ac.jp/dep/surg/pg45.html